Kelvn | Istock | Getty Photographs
Shares of Japanese drugmaker Sumitomo Pharma fell 15.60% Friday on what seemed to be profit-taking, a day after the federal government endorsed the corporate’s iPS cell-based remedy for Parkinson’s and coronary heart illness.
Sumitomo Pharma’s inventory, which rose greater than 300% in 2025, hit its highest stage since 2019 final week amid rising confidence in its Parkinson’s remedy. The therapies depend on induced pluripotent stem (iPS) cells — grownup cells which can be reprogrammed again right into a stem-cell-like state.
Stem cells are are able to self-renewal and work as a restore system, changing broken cells and sustaining tissues, permitting them for use in regenerative medication.
“Whereas the remedy might probably see widespread use and turn into a blockbuster in Japan and the US over the long run, we count on nearly no revenue contribution close to time period,” mentioned Citigroup World Markets Japan’s analyst Hidemaru Yamaguchi.
Sumitomo’s inventory has been overheated, and up to date features have been “extreme,” he added.
In accordance with Japan’s Ministry of Well being, Labor and Welfare, formal approval shall be granted inside the subsequent one to 2 months, NHK reported.
The endorsement comes years after Kyoto College professor Shinya Yamanaka, who later gained a Nobel Prize for his stem cell analysis, first succeeded in producing iPS cells from mice in 2006.
Japan has been striving to develop stem-cell therapies, with Kyoto College’s CiRA, which runs a clinical-grade iPS cell financial institution, offering researchers entry to ready cells that can be utilized in trials for a variety of circumstances.
Sumitomo Pharma develops and markets prescription medicines throughout a number of therapeutic areas, together with neuroscience, oncology and regenerative medication.
